{"name":"OX2 Therapeutics","slug":"ox2-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Treatment with hP1A8","genericName":"Treatment with hP1A8","slug":"treatment-with-hp1a8","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Treatment with hP1A8","genericName":"Treatment with hP1A8","slug":"treatment-with-hp1a8","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPUGZEY2JIYWN3Y2dqeF9RYmtwWlBqa3Nxd1RodUNNOGI3THlfbzBLLVNGaUV1ZXZXMlkzTzluYmFBbzZnckdOSFd0NktuRUFLZkhvOWlwZWJTUkxSaDRfSkUyanFyWndvRnF3aTdJRjhIZWVabkE2NVJaZVNaaEJjeFc0dGIycnktSENVZTJOSGp0aFdxNzRNOEF5a0xOeGRJd01SLVBVTXR2bzNBU2xMYjhqVVMyU1lUOFE5Tzd6ellITkhqcUs3NHVwcEVOTUI5UHFZTTRiU3EtLU1OVkpOanZnVzVBa3lRaDA2X3hYUUtUM3ZqYWFScjFn?oc=5","date":"2026-03-21","type":"trial","source":"Barchart.com","summary":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight - Barchart.com","headline":"Recurrent Glioblastoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYXdoeDVHWUNQY0lzbFJuZGE1R2tJTjZISzRVR1dhazlLRDJHLTd3U1hmcDlzMlM5YTJwZ3M5OHR2WUsxeWQ1eEdGTDlDWU9veG5qUHJ5anJqZUFUZFp4NHlDZ2NPa0JQNWxNcHJLcmJPWWRnd1I2eG04UTVOd3F2R1pqbldVaUNwWUpBQUh2NTRkWUVWZl93MW5PSG1pRWtxYno3SmdVbGcwUQ?oc=5","date":"2025-07-09","type":"pipeline","source":"BioWorld News","summary":"Idorsia Pharmaceuticals divulges new orexin OX2 receptor agonists - BioWorld News","headline":"Idorsia Pharmaceuticals divulges new orexin OX2 receptor agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVG9PN1JvTmw0Z24tdm1NRWdQbmtCeGxnRFpjSi1rcExMcC1pc0pXd3pmUEVHZWluTndkQU5kNGtkRk83RGNlenNYYUVuY1ZEWXJPMllTU1VQSFkxTmJOUUFJZ3U3RnFrOThvNWd5VTVXQ2FvSlFjNEdfenA4b2tGV21yQXlFZThVTlUyVl9KVQ?oc=5","date":"2024-12-30","type":"pipeline","source":"BioWorld News","summary":"Lundbeck reports orexin OX2 receptor agonists - BioWorld News","headline":"Lundbeck reports orexin OX2 receptor agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTFBsN0lMRERoNzJYYzdWV2dCdlNmWU42cmQ1QUV3N3pzMTM0eklMVFBxTnlUT1Q3dXdMU0drNzV6QWg5T1JwQzVLa01pQ05nQnQwOE1ZdGlpMWtyM3U5THc5QlZuYWFXeDdxYnFkSzhaa3pNZlJyTVE?oc=5","date":"2024-11-15","type":"pipeline","source":"MedPage Today","summary":"MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1 - MedPage Today","headline":"MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE40djR2TlU5c1ZVaF9hZUpOSm9xRHVFeEs4enJvZWQ1b1JHUTdhV0x2bGxNaFFqMEN6UWEtUVpCOWdSS0RPRHdQcmtOQWY2TUNwZ1JYR2N0OVIxMWZ2a0RBb1B2cUg4enE2OHZxVHNKYUd0Q2c?oc=5","date":"2024-11-01","type":"pipeline","source":"MedPage Today","summary":"Novel Drug Improves Depression, Insomnia Symptoms as Add-On Therapy - MedPage Today","headline":"Novel Drug Improves Depression, Insomnia Symptoms as Add-On Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPUEYzRFFLTm03anR6Y2tqZm9ZRkZCVmttWnh1SzFxWW1VZk1pbjJidDUzOTR3M2dVQUNrUFVneU5sUlhmVU1RbWt6eU9lSGFxRG9BV2VHYUhoWkw4Tnh4UUZqYVpBTUJJWlluLUVBODVvNW10VDJxUno5NWw4MnZOY0NWRU5LU3kxWTlQQVFpRFZLUGpG?oc=5","date":"2024-09-03","type":"pipeline","source":"BioWorld News","summary":"Vertex discovers new orexin OX2 receptor agonists - BioWorld News","headline":"Vertex discovers new orexin OX2 receptor agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQUGZZQnd6ZkQwRzhpV3VwSEItZXFpM3FIOXVNakFBYW5OUWs1MGR0cmN0aUJQSU0tc0xvNmZuclNiN2p4RkxmaGZtQ3Qzb1hrUmI2a2dtbjVlMWUzamFLbjlxOTAtNVhyWU9lQnJjZmNVWFFBMVdydlU5aXFRTi03YXVXUmdTb3VZaWVSSDZKZWJ2SU5FT1ppZ2FmZWQyVEk2MVU0X01hRlNvcnNMbEJNMDRHby0?oc=5","date":"2024-06-28","type":"patent","source":"BioWorld News","summary":"Takeda Pharmaceutical patents orexin OX2 receptor agonists for narcolepsy - BioWorld News","headline":"Takeda Pharmaceutical patents orexin OX2 receptor agonists for narcolepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPTG9UcU5RenotRDNfeS1kUmpzM2x0SXk3T3hLV3ZTdlBuZHBWaFEyS1I2VlF0dTVXRVpnRG1HRXdhMGszb3VJRzYwZFVfcVhEOVBOT2hLVVFDekFnLXlxSmw4Vm8wNjg0RV9HYlZ2RlJtWVZTaVlITmVTcFZXa3p1Z1VlWDExMjBFcW9fYlkzYVZhT3ZNUGc2bWZXZ0tZQmM?oc=5","date":"2024-06-21","type":"patent","source":"BioWorld News","summary":"Orexin OX2 receptor modulators disclosed in Vertex patent - BioWorld News","headline":"Orexin OX2 receptor modulators disclosed in Vertex patent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVU94UmxFWUFYR2NGTzhINTcxNnMzazc1MDZKVXllUURmSFRtWENsTC1LeXdlWHB0aHJhZHlvZllHbktFdlIxekVKSzQtckZtNTF4ZmdXNjR0WHM2c0tzcWdCaVZCbXoxem1jYUs2WGNTb2I1WHl6S29sR055bFhqSWFEZHRvT3JtVC02T1dpYV9PMFZPeHhXbm54MVZiQzNocEQ4aEdQQW51VmRDWEZJOGI5N2hIc05GMjc0?oc=5","date":"2024-05-08","type":"pipeline","source":"BioWorld News","summary":"Kissei Pharmaceutical presents new orexin OX2 receptor agonists for narcolepsy - BioWorld News","headline":"Kissei Pharmaceutical presents new orexin OX2 receptor agonists for narcolepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNMjhoREJFTDlwdXkyQk5tNVlKOHh5b3dMY2pka2g2dUIxYk84dmZhNTRfWmRIVW5qb21BdkcyajRHZ2dYNkRaUFpSeGtTYkNOYU1Hbm5JQngySGR3T1o2ZUlPSmtxX3M2R1dFVjI5Tm10cGxSVk83RGlfSWEtTjkzbVAyM0FXdmo1cVBNWWdFZU9hUVVwOVcyejN0ZVlNS09JQUJURVZB?oc=5","date":"2023-09-26","type":"pipeline","source":"BioWorld News","summary":"Orexia Therapeutics describes new orexin OX2 receptor agonists - BioWorld News","headline":"Orexia Therapeutics describes new orexin OX2 receptor agonists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPeWpNMi1Wam53ZE9GWkpINzRCQXhUT3ZfcThIVXpjMzNFa3JBNVY1aU8wcVRsdVZLNWdnMTJIRi1hbGJfTlJJQzg0Ym9hT2l3ek9BcmUwYmVPTXBmeHR4dTRXWk1UOWc3Smk5c3RGY19HZFlVMXpmTm5nRHZEZy1yV3hMRnBlT3hSajRQYW5n?oc=5","date":"2023-06-27","type":"pipeline","source":"Frontiers","summary":"Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade - Frontiers","headline":"Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPa1VWdF9nZTRQTEFJWkgtdkt3eVVPR0F0ZG9ybzcySjFEVkZLU2ducHpPVkVibVlWM2FKX0Joc3VkMHFnLXM5T1U4TGxZNE5XZUFaa2o5WFJxeTJuTDdtUDYzWWZuX3lFZHN4TUotSW1yQ2xqMW9JTkRHdEVMN3ctQlJjMHV0dksxMjR6VkNKREdTb2pBZU5FVTNDVXcyRWt6WVRB?oc=5","date":"2022-10-27","type":"patent","source":"BioWorld News","summary":"Orexia Therapeutics patents new orexin OX2 receptor agonists - BioWorld News","headline":"Orexia Therapeutics patents new orexin OX2 receptor agonists","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}